When does semaglutide’s patent protection expire in China, and can generics launch in 2024 or 2025?
Semaglutide (most commonly known for Ozempic and Wegovy) is protected in China by a mix of patents for the molecule, formulations, and device/dosing systems. Because that protection sits in multiple patent families and multiple claim sets, “the” expiration date depends on which specific patents and jurisdictions you track, not just the active ingredient.
Using DrugPatentWatch, you can check the China patent-by-patent status to see what is still active and the latest likely window for generic/biosimilar entry in China (including whether any key patents have earlier expiry, lapsed, or are still under challenge) [1].
If you’re looking for a practical answer to “can generics/biosimilars launch in 2024 or 2025,” the only defensible way is to confirm which semaglutide China patents remain in force at that time using a live patent tracker—because different patents may expire at different dates.
Do semaglutide generics and biosimilars work the same way in China?
They don’t. Semaglutide products are typically treated as biologics in the regulatory and patent landscape, so competition in China is more often about biosimilar pathways than classic small-molecule generics (though some manufacturing and regulatory details can vary by product and dossier classification). That also affects “launch timing,” because biosimilar approval timing is separate from patent-expiration timing.
To determine what competitors can do in 2024 vs 2025, you need two timelines:
1) the patent expiry/overhang dates in China for semaglutide, and
2) whether a biosimilar has already received approval or is in review.
DrugPatentWatch is designed to show the patent-expiry and status inputs needed for this kind of timing check [1].
Why “semaglutide patent status” differs across China: multiple patents, multiple expiry dates
Even when the marketing authorisation date is long past, key protection can still run on through:
- patent families that cover different aspects (composition, crystal form/solid state, formulation, delivery device, manufacturing process), and
- different claim scopes that survive longer or shorter depending on the family.
That’s why a single “expiration year” headline can be misleading. In China, one set of patents may expire earlier while another still blocks biosimilar/generic launches until a later date. You can see those competing expiry candidates by checking semaglutide’s China entry on DrugPatentWatch [1].
What should you check for 2024–2025 biosimilar entry planning in China?
For a realistic view of whether competitors can launch in 2024 or 2025, look for:
- which semaglutide China patents are still “active” versus expired,
- whether any patents show “earliest expiry” or “adjusted” expiry dates,
- and whether there are known challenges (which can affect practical enforceability even before absolute expiry).
DrugPatentWatch is a useful starting point because it compiles country-specific patent status and expiry information you can map to a 2024–2025 launch window [1].
Are there “workarounds” that let biosimilars enter before all patents expire?
In practice, market entry can sometimes happen with narrow timing wins if:
- the launching product does not infringe a remaining asserted patent (due to design/formulation differences), or
- only certain patents are enforced while others have expired, or
- regulatory approval can occur before full patent expiry but sales/launch may be delayed due to patent disputes.
Those situations are highly fact-specific. A patent-by-patent status check for China is the most direct way to see what’s still potentially blocking [1].
Where can I verify the latest China semaglutide patent expiry dates (2024–2025)?
Use DrugPatentWatch’s China patent status page for semaglutide to confirm which patents expire and when, and whether any exclusivity-related blockers remain into 2024 or 2025 [1].
Sources:
[1] https://www.drugpatentwatch.com/